UNSPSC 51372005: Cyprenorphine

This classification denotes an opioid receptor agonist with the molecular formula C26H33NO4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1P6HEG5ZHS, chemically known as 6,14-ethenomorphinan-7-methanol, 17-(cyclopropylmethyl)-4,5-epoxy-3-hydroxy-6-methoxy-alpha,alpha-dimethyl-, (5alpha,7alpha)- but generally known as cyprenorphine, which bears US NIH Compound Identifier 20435. European Medicines Agency schedules Cyprenorphine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06873MIG.

UNSPSC 51372005 Cyprenorphine is a Commodity code that in recent state and local procurement activity covers the supply of pharmaceutical products, including naloxone, generic multi-source pharmaceuticals, and over-the-counter products, rather than cyprenorphine specifically. The work involves manufacturing and wholesale distribution of FDA-compliant medications to state agencies, counties, and cooperative purchasing alliances, with vendors required to maintain cGMP certification, Drug Supply Chain Security Act compliance, and contractual relationships with authorized pharmaceutical wholesalers. State and local buyers under this code include county health departments, state health and human services commissions, and multistate cooperative purchasing organizations; the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) and Texas Health and Human Services Commission stand out as recent soliciting bodies.

Geographic activity appears concentrated in Minnesota, Texas, and Florida based on recent opportunities. Seminole County, Florida issued IFB 60459723LAS in June 2026 for 1,900 units of naloxone and 800 safe drug deactivation systems annually with a response deadline of July 26, 2023, requiring quarterly deliveries and vendor responsibility for shipping costs. The Minnesota Department of Administration's Office of State Procurement, administering MMCAP, issued RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products across participating state and local facilities with a March 26, 2026 response deadline and July 1, 2026 contract start date; the RFP emphasized price competitiveness (75 percent of evaluation weight) and required submission through the ePro procurement system with pricing in CSV format. The Texas Health and Human Services Commission issued RFI HHS0017013 in April 2026 seeking vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, signaling the state's exploration of direct contracting models outside traditional pharmacy benefit manager and group purchasing organization channels. Vendors typically must carry $5,000,000 commercial general liability coverage, comply with E-Verify employment verification, and accept two-year initial contract terms with renewal options.